Cardiac CT Evaluation of EAT in AF vs. Non-AF Subjects

NCT ID: NCT07320261

Last Updated: 2026-01-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-01

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this cross-sectional study is to explore the relationship between atrial structural characteristics (such as epicardial adipose tissue infiltration and atrial size) and atrial fibrillation (AF), as well as the differences in these characteristics among different AF subtypes. It will also clarify the independent association between pericardial fat distribution and AF (and its subtypes) after excluding confounding factors.

The main questions it aims to answer are:

* What are the differences in epicardial adipose tissue volume and atrial size among patients with sinus rhythm, paroxysmal AF, and persistent AF?
* Is pericardial fat distribution independently associated with AF and its subtypes after adjusting for confounding factors such as age, hypertension, and left atrial enlargement?

Researchers will enroll patients who undergo coronary CTA or left atrial CTA at The Second Affiliated Hospital of Zhejiang University School of Medicine, and match and divide them into three groups (sinus rhythm group, paroxysmal AF group, and persistent AF group) based on BMI and other factors. They will compare the differences in pericardial fat distribution and baseline characteristics among the three groups and analyze the independent association between pericardial fat and AF.

Participants will:

* Provide relevant clinical baseline data and CTA examination results
* Complete the collection of demographic information, medical history, and laboratory test data

The study duration is 6 months, starting from the date of ethical approval, with an expected end date of June 2026. A total of 600-900 participants (200-300 per group) will be enrolled to ensure the reliability and clinical applicability of the research conclusions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation (AF) CT

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Paroxysmal AF

No interventions assigned to this group

Persistent AF

Paroxysmal AF

No interventions assigned to this group

Sinus rhythm

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who undergo coronary CTA or left atrial CTA examination at The Second Affiliated Hospital of Zhejiang University School of Medicine;
* Aged 18 years or older
* Cardiac rhythm status is confirmed as sinus rhythm, paroxysmal atrial fibrillation, or persistent atrial fibrillation;
* Willing to provide clinical baseline data and allow access to CTA examination results;
* Able to understand and cooperate with the data collection process of the study.

Exclusion Criteria

* Patients with incomplete clinical baseline data or unreadable CTA images;
* Aged less than 18 years
* Patients who refuse to participate in the study or cannot cooperate with data collection;
* Other situations judged by the researchers to be unsuitable for inclusion in the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Auckland, New Zealand

OTHER

Sponsor Role collaborator

xiaoya wang

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

xiaoya wang

Associate Chief Physician

Responsibility Role SPONSOR_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xiaoya Wang, Doctor

Role: CONTACT

86-0571-87784704

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-1638-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.